Anti-D Rho immunoglobulin

Drug Profile

Anti-D Rho immunoglobulin

Alternative Names: Anti-D immunoglobulin; WinRho SDF

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cangene Corporation
  • Developer Baxter Healthcare Corporation; Emergent BioSolutions
  • Class Immunoglobulins
  • Mechanism of Action Immunoglobulin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura
  • No development reported Dengue; Thrombocytopenia

Most Recent Events

  • 28 Sep 2017 Saol Therapeutics completes the acquisition of Anti-D Rho immunoglobulin from Aptevo Therapeutics
  • 31 Aug 2017 Saol Therapeutics enters agreement to acquire Anti-D Rho immunoglobulin from Aptevo Therapeutics
  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top